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In the Asia Pacific region, chronic hepatitis B (CHB) is an
endemic infection, and is the most important cause of cir-
rhosis and hepatocellular carcinoma (HCC). The under-
standing of the natural history of CHB through large
longitudinal population studies has been pivotal in identi-
fying risk factors which are important for disease progression
[1, 2]. Well-established risk factors include host factors, such
as age and gender, and viral factors, such as genotype and
viral load. The interplay between other types of liver diseases
and CHB is less well studied. Non-alcoholic fatty liver dis-
ease (NAFLD), an entity which has traditionally been asso-
ciated with Western populations, is now becoming more
prevalent in many parts of Asia. This is partly due to the rising
prevalence of obesity in the Asia Pacific countries. There-
fore, it is unavoidable that there will be an increasing trend of
NAFLD co-existing with other liver diseases. The effects of
NAFLD on viral hepatitis have been described mainly in
patients with chronic hepatitis C. In this setting, the presence
of steatosis can potentially accelerate fibrogenesis, increase
the risk of cirrhosis and hepatocellular carcinoma (HCC),
and reduce the efficacy of antiviral therapy [3].
In contrast to chronic hepatitis C, the data regarding the
effect of steatosis on CHB, and vice versa, is sparse. This is in
spite of the fact that an increasing proportion of CHB patients
have evidence of steatosis. There are currently no human
studies implicating hepatitis B virus (HBV) to be steatogenic.
To date, only studies using transgenic mice have
demonstrated the ability of HBV protein X to induce the
expression of lipid synthesis genes [4]. In humans, steatosis
appears to be mediated predominantly by host demographic
and anthropometric factors and the presence of metabolic
factors such as diabetes mellitus, hypertension, and dyslipi-
demia. A recent study by Wong et al. [5] on 91 CHB patients
and 922 controls showed that HBV infection was indepen-
dently associated with a lower rate of steatosis after adjusting
for demographic and metabolic factors (adjusted OR 0.42,
95 % CI 0.20–0.88). Therefore, in humans, HBV does not
appear to be steatogenic and, in fact, may have the opposite
effect.
The role of steatosis as an independent factor on CHB
outcome is also not well defined. Large population cohorts
have shown that the presence of obesity and metabolic
syndrome are associated with increased risk for liver cir-
rhosis and HCC in patients with CHB. A study of 2,903
male CHB patients with a mean follow-up of 14.7 years
identified excess body weight as a significant risk for HCC
development and liver-related mortality [6]. Chen et al. [7]
demonstrated a higher risk for developing HCC in 3,931
CHB patients, with diabetes being a significant association.
A study of 1,566 CHB patients by Wong et al. [8] showed
an increased risk of cirrhosis for those with underlying
metabolic syndrome. Although metabolic factors appear to
be risk factors for the development of cirrhosis and HCC in
CHB, the role of steatosis as an independent risk factor is
not conclusive. The lack of association between steatosis
and fibrosis/cirrhosis in CHB has been shown in several
studies. Furthermore, a seemingly paradoxical relationship
has been observed in studies showing a potential protective
role of steatosis in reducing the severity of liver disease in
CHB. A meta-analysis of 7 studies comprising 3,067
patients shows a negative effect of steatosis on viral load,
with a standardized mean difference of -74.12 (95 % CI,
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-82.93 to -65.31) [9]. Shi et al. [10] reported a signifi-
cantly lower rate of F C 2 fibrosis in 260 CHB patients
with steatosis compared to 1,655 without steatosis (39.6 vs.
53.5 %, respectively, P \ 0.05). Another study of 86 males
with CHB showed no significant association between sig-
nificant fibrosis and the presence of steatosis [11]. Like-
wise, a recent study of 174 CHB patients showed no
significant difference in fibrosis or necroinflammation
between those with and without steatosis [12].
Although the effect of steatosis on the severity of liver
disease in CHB continues to be uncertain, even less is known
about its role in the natural history of HBV infection. The
transition from the immune-tolerant phase to the immune-
clearance phase and to subsequent HBeAg seroconversion,
and occasionally to HBsAg seroclearance, is largely
immune-mediated. Given the lack of pathophysiological
linkage between steatosis and HBV, the role of steatosis is
likely to be minimal in these instances. In a previous study
from 2007, Chu et al. [13] performed a case–control study
looking at 54 HBsAg carriers with evidence of HBsAg se-
roclearance and compared it with 108 carriers without
HBsAg seroclearance matched for age and sex. The study
reported a higher percentage of moderate–severe steatosis in
those with HBsAg seroclearance, and concluded that stea-
tosis may have contributed to the loss of HBsAg. The
mechanisms for this observed phenomenon is unclear,
although the authors surmise that the presence of fat within
the hepatocytes may alter HBsAg cytoplasmic distribution
and lead to subsequent seroclearance. A further proposed
mechanism postulated that steatosis may induce apoptosis
which may in turn contribute to the loss of HBsAg. However,
it is unlikely that any firm conclusion can actually be drawn
from this initial study. The quality and the selection criteria
of the control subjects are critical in any case–control studies.
In this particular study, it is insufficient to match only for age
and gender without the consideration of important viral
parameters such as genotype and viral load. Also, no infor-
mation was given as to whether the controls were consecutive
patients who fulfilled their matching criteria. A multivariate
analysis is also needed to determine whether in fact steatosis
itself or other factors such as obesity or metabolic risk factors
were more important in causing HBsAg seroclearance.
In this issue of Digestive Diseases and Sciences, Chu
et al. [14] performed a follow-up study looking only at the
patients who achieved HBsAg seroclearance. Of the 155
patients studied, they observed that those with hepatic
steatosis achieved HBsAg at a younger age compared to
those without steatosis (49 vs. 53 years, respectively,
P = 0.001). One can assume that a third of the patients of
this study were in fact from the initial study. Concerning
the new analysis, steatosis is either present or not present,
and should not be subjected to any other arbitrary classi-
fications. Classifying the patients with mild steatosis and
the patients with no steatosis into the same group is flawed.
Furthermore, since HBsAg seroclearance is a function of
time, whether it occurs at an earlier age in patients with
steatosis can only be answered by the use of Kaplan–Meier
analysis. Multivariate analysis is also needed to determine
whether indeed steatosis is a significant factor rather than a
co-factor of potentially more important attributes such as
obesity, hyperlipidemia, lipid lowering agents, and other
metabolic factors.
In fact, spontaneous seroclearance of HBsAg is a rare
event in patients with CHB, with an estimated incidence of
0.1–0.8 % annually. This alone makes any studies on
HBsAg seroclearance difficult, especially when it usually
occurs late in the course of infection. In order to ascertain
any definite factors which may contribute to HBsAg se-
roclearance, large population studies of unselected CHB
patients are required, and the patients need to be prospec-
tively followed up over a long period of time. It is therefore
difficult to draw conclusions based on a case–controlled
study and a retrospective cohort study from a single center
using a very similar group of patients. As steatosis and
metabolic factors are strongly associated with each other, it
is also imperative to ensure that these confounding factors
are taken into consideration, as they may all have potential
effects on the course of HBV infection. Previous large
population studies have shown that, even though the
presence of metabolic factors is associated with worse liver
outcomes in CHB, steatosis was not an independent con-
tributor after controlling for other metabolic components. It
is also likely that viral factors such as replication fitness
and genotypes, and viral suppression by antiviral therapy,
should be predominant factors in HBsAg seroclearance.
The presence of low or undetectable HBV DNA would also
be a prerequisite factor. In a study of 3,087 CHB patients
by Liu et al. [15], 562 patients underwent HBsAg seroc-
learance after 24,829 person–years of follow-up. Viral load
at baseline and its reduction during the follow-up period
were the strongest predictors of HBsAg seroclearance.
Interestingly, this study also demonstrated that extreme
obesity (BMI C30 kg/m [2]) in men regardless of age was
also associated with seroclearance of HBsAg. Whether this
is due to underlying steatosis is not known.
In recent years, we have seen an exponential increase in
studies examining the use of quantitative HBsAg levels for
predicting disease outcome and treatment response [16].
This provides the perfect opportunity to study the kinetics
of levels of HBsAg in patients undergoing HBsAg seroc-
learance. It is likely that, if indeed steatosis does have a
favorable effect on HBsAg seroclearance, this will be
reflected by a decline in HBsAg levels over time—a trend
that should be observed prior to seroclearance. As HBsAg
seroclearance is uncommon, measuring HBsAg levels can
be an important tool to provide vital clues to either support
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or refute the beneficial effects of steatosis in HBsAg
seroclearance.
It is important to stress that, although metabolic factors
and steatosis are strongly linked, they may independently
have different effects on CHB. The real difficulty is in
separating out these factors in order to identify the true
effects of steatosis. The evidence thus far demonstrates that
metabolic risk factors including obesity are detrimental to
the progression of HBV disease, with increased risk of
cirrhosis, HCC, and liver-related mortality (the findings of
Liu et al. [15] being the exception). Steatosis, however,
appears to be favorable in some instances with less fibrosis
and lower viral loads. Chu et al. [13, 14] in their two
studies found that steatosis may have a favorable effect on
HBsAg seroclearance. This unexpected finding deserves
further well-designed studies to confirm and to examine for
the possible mechanisms.
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